RollingStone Co Ltd

RollingStone Co Ltd has a price-to-book ratio of 1.2 and a price-to-tangible-book ratio of 1.2, indicating that the market value is slightly above the book value of the company's tangible assets. The company's liquidity position is strong, with a current ratio of 2.83 and cash and equivalents amounting to 17,942,439,830 KRW. However, the company's operating cash flow is negative at -10,099,915,010 KRW, suggesting that it is not generating sufficient cash from operations to sustain its activities. In terms of profitability, RollingStone Co Ltd is currently unprofitable, with a net income of -17,500,196,130 KRW and a return on equity of -1.0977. The company's return on assets is also negative at -0.69, indicating that it is not effectively utilizing its assets to generate profits. The gross profit is negative at -2,785,539,850 KRW, further highlighting the company's challenges in maintaining profitability. The company's revenue is distributed across four segments: Molecular Diagnosis, Biochemical Diagnosis, Immunodiagnostic Business, and Other Business. The revenue concentration data is not provided, but the company's operations are primarily focused on the healthcare equipment sector. The geographic exposure is not specified, but the company is based in Korea. RollingStone Co Ltd's growth trajectory is uncertain, as the company is currently experiencing a decline in profitability. The company's operating income is negative at -12,006,628,070 KRW, and the free cash flow is also negative at -25,088,290,490 KRW. The capital expenditure is -8,571,686,360 KRW, indicating that the company is not investing in new projects or expanding its operations. The risk assessment for RollingStone Co Ltd indicates a low liquidity risk and a low dilution risk. There are no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.43, suggesting that it is not heavily leveraged. However, the company's negative operating cash flow and free cash flow indicate potential liquidity challenges. Recent events related to RollingStone Co Ltd include the company's transition from The BioMed Co Ltd to its current name. The company's focus on in-vitro diagnostic (IVD) medical equipment and devices is a key aspect of its business strategy. The company's financial performance and strategic direction will be closely monitored in the coming periods.